This article was accepted into the corpus but its outbound wikilinks were never NER-processed — typical at the deepest BFS hop or when the run's entity cap was reached. No expansion funnel to show.
| SATT Paris-Saclay Valorisation | |
|---|---|
| Name | SATT Paris-Saclay Valorisation |
| Type | Technology transfer company |
| Founded | 2012 |
| Headquarters | Paris-Saclay |
| Region | Île-de-France |
| Parent organisation | Université Paris-Saclay consortium |
SATT Paris-Saclay Valorisation is a French technology transfer acceleration company created to bridge research from public laboratories to industry, linking academic innovation with industrial application. It operates within the Paris‑Saclay innovation ecosystem, interacting with universities, grandes écoles, public research organizations, and private firms to valorize intellectual property and spin out start‑ups. The company engages with a broad network including universities, research institutes, hospitals, investors, and regional authorities to translate scientific results into marketable technologies.
SATT Paris-Saclay Valorisation was established in the early 2010s as part of a national initiative following reforms that affected institutions such as Université Paris-Saclay, Commissariat à l'énergie atomique et aux énergies alternatives, Centre national de la recherche scientifique, Institut national de la santé et de la recherche médicale, and Institut national de recherche en informatique et en automatique. Its creation aligned with policies influenced by leaders from Ministry of Higher Education and Research (France), with implementation coordinated alongside entities like Direction générale des entreprises, Agence nationale de la recherche, and regional stakeholders including Conseil régional d'Île-de-France. The SATT built upon precedents set by valorisation offices at École Polytechnique, Université Paris-Sud, École normale supérieure, and laboratories associated with CEA Saclay and INRIA Saclay. Over time, it interacted with innovation actors such as BPI France, French Tech, Cap Digital, and clusters including Systematic Paris‑Region and Medicen Paris Region.
The mission centers on identifying inventions from institutions like Université Paris-Saclay, Equipex, CNRS, Inserm, and CEA, protecting intellectual property with offices such as INPI and developing commercialization pathways through licensing, start‑up creation, and partnerships with industrial players including Sanofi, Dassault Systèmes, Thales, and Schneider Electric. Activities include patent strategy with service providers, prototyping in facilities akin to Plateforme technologique, market studies referencing data from INSEE and Eurostat, and mature project acceleration using networks like Business Angels des Cités and investor groups such as Partech Ventures and Elaia Partners.
Governance is shared among stakeholders including founding institutions such as Université Paris‑Saclay, CNRS, CEA, INSERM, ENSTA Paris, École Polytechnique, and regional authorities like Saclay plateau management. The board comprises representatives from academia, industry, and public investment bodies including BPIfrance. Executive management works with technology managers, legal counsel, and project managers who liaise with laboratories such as Laboratoire de Génie Chimique, Laboratoire de Physique des Solides, and clinical research centers affiliated with Assistance Publique–Hôpitaux de Paris. Organizational units coordinate with accelerators like Station F and incubators such as Incubateur HEC and Agoranov.
The technology transfer pipeline involves invention disclosure from teams at institutions like Université Paris-Sud, ENS Paris Saclay, INRAE, and Geoazur; evaluation by scientific committees drawn from networks including Académie des sciences and industrial experts from Airbus and Veolia; IP protection via INPI filings; proof‑of‑concept development leveraging platforms akin to Carnot Institutes; licensing negotiations with corporations such as TotalEnergies and Safran; and spin‑off creation supported by accelerators including Le Village by CA and investors like Amundi. The process uses standard instruments recognized by bodies such as Organisation européenne des brevets and aims to meet criteria set by grantors like European Research Council and Horizon 2020 programs.
Significant outcomes include spin‑offs and licensed technologies in sectors spanning biotechnology collaborations with firms like bioMérieux and Sanofi, advanced materials projects involving Arkema and Saint‑Gobain, and software/AI initiatives aligned with Google DeepMind‑style research partnerships and computational platforms used by CEA. Notable examples draw on translational research from laboratories such as Laboratoire Kastler Brossel, Institut Pasteur, Institut Curie, and Laboratoire de Physique Théorique, resulting in collaborations or transactions with multinational companies including Microsoft, IBM, and Siemens. The SATT has contributed to the creation of start‑ups that attracted funding from venture capital firms like Kreos Capital and Bpifrance Le Hub.
Collaborations extend to universities and grandes écoles such as Université Paris-Saclay, École Polytechnique, Paris‑Saclay University, Télécom Paris, and CentraleSupélec; research organizations like CNRS, CEA, INSERM, INRAE, and INRIA; industry partners including Sanofi, Thales, Airbus, and Schneider Electric; and regional innovation actors like Medicen, Systematic Paris‑Region, and Cap Digital. The SATT engages with funding and acceleration networks such as BPI France, European Investment Bank, EIT Health, Innovative Medicines Initiative, and international partners from clusters like Silicon Valley incubators and Cambridge Innovation Center.
The financial model combines committed capital from founding institutions including Université Paris‑Saclay and CNRS, competitive grants from entities like Agence nationale de la recherche and European Commission programs, public investment instruments including BPI France facilities, and revenues from licensing and equity stakes in start‑ups backed by investors such as Partech Partners and Seventure Partners. The SATT also leverages seed funds, crowd‑funding platforms modeled on KissKissBankBank, and co‑investment schemes with corporate venture arms like Sanofi Ventures and Schneider Electric Ventures to support maturation and market entry.